.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, clients with metastatic stomach lumps who obtained biomarker-matched therapies based on circulating growth DNA profiling presented a better clinical benefit than those obtaining unmatched treatment.